Open AccessCrohn�s disease and cystic fibrosis: there is still a lot to learn
Author(s) -
Claudio Trigo Salado,
Eduardo Leo Carnerero,
María Dolores de la Cruz Ramírez
Publication year - 2018
Publication title -
revista española de enfermedades digestivas/revista española de enfermedades digestivas
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.331
H-Index - 38
eISSN - 2340-4167
pISSN - 1130-0108
DOI - 10.17235/reed.2018.5725/2018
Subject(s) - medicine , calprotectin , cystic fibrosis , capsule endoscopy , inflammatory bowel disease , crohn's disease , inflammation , disease , gastroenterology , fibrosis , dysbiosis , pathophysiology , intestinal permeability , pathology
The relationship between cystic fibrosis (CF) and the risk of developing inflammatory bowel disease (IBD) is not clear. CFTR mutations can influence dysbiosis and increased intestinal permeability, which are two key elements in the pathophysiology of IBD. These patients have increased intestinal inflammation, as demonstrated by increase pro-inflammatory gene expression in the bowel, specific fecal markers (fecal calprotectin), gross lesions (capsule endoscopy) and histological lesions on examination of surgical specimens.